Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

STATEMENT BY APPLICANT Filing Date April First Named Inventor R.C.	00,125 10, 2002	
STATEMENT BY APPLICANT Filing Date April First Named Inventor R.C.		
First Named Inventor R.C.	M/s in stop	
Crown Add Holis	Warrington	$\overline{}$
Group Art Unit 161	1	ယ်
(use as many sheets as necessary) Examiner Name Fred	lerick Krass	
Sheet 1 of 2 Attorney Docket Number 102	12-32	

			U.S. PATENT [DOCUMENTS		
Examiner Cit Initials No	Cite	Cite Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant	
	No.1	Number - Kind Code ² (if known)	MM-DD-YYYY		Passages or Relevant CS Figures Appear	
		US-			40	
		US-				
	1	US-				
		US-				
		US-				
		US-				
	1	US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-			<u>,</u>	
		US-				
		US-				
	1	US-				

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	0.11	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	۳°
	No.1					
						
		+			* -	

Examiner Signature	Date Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.
³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ³ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0561-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO Complete if Known **Application Number** 09/600,125 INFORMATION DISCLOSURE April 10, 2002 Filing Date STATEMENT BY APPLICANT R.C. Warrington First Named Inventor **Group Art Unit** 1614 (use as many sheets as necessary) **Examiner Name** Frederick Krass 10242-32 Attorney Docket Number Sheet of 2

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS				
Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of		T 2		
1.	WARRINGTON, R.C. et al., "Modulation of anticancer drug toxicity by L-histidinol: A route for improving human cancer chemotherapy?", Drugs of the Future, 1993, pp. 743-749			
2.	WARRINGTON, R.C. et al., "L-Histidinol in experimental chemotherapy: improving the selectivity and efficacy of anticancer drugs, eliminating metastatic disease and revering the multi-drug resistant phenotype", Biochemistry & Cell Biology, 1992, pp. 365-375, Vol. 70.			
3.	WARRINGTON, R.C. et al., "Hitidinol-Mediated Enhancement of the Specificity of Two Anticancer Drugs in Mice Bearing Leukemic Bone Marrow Disease", Journal of the National Cancer Institute, 1985, pp. 1070-77, Vol. 71.			
	·			
-				
	· · · · · · · · · · · · · · · · · · ·			
	1. 2.	Cite No.1 Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the ltem (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. WARRINGTON, R.C. et al., "Modulation of anticancer drug toxicity by L-histidinol: A route for Improving human cancer chemotherapy?", Drugs of the Future, 1993, pp. 743-749 WARRINGTON, R.C. et al., "L-Histidinol in experimental chemotherapy: improving the selectivity and efficacy of anticancer drugs, eliminating metastatic disease and revering the multi-drug resistant phenotype", Biochemistry & Cell Biology, 1992, pp. 365-375, Vol. 70.		

Examiner Signature	Krass	Date Considered	oz/eff
(')	• • • • • • • • • • • • • • • • • • • •		

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.